Boeing is starting to show progress in its turnaround plans. So why is the stock still tanking? Shares of the plane maker ...
Investor's Business Daily on MSN57m
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit TherapeuticsMerck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback